Skip to main content
. 2021 May 18;5(4):pkab045. doi: 10.1093/jncics/pkab045

Figure 2.

Figure 2.

Comparison of the adjusted mean and median insurance payment and out-of-pocket (OOP) expenses for total and discarded amount of weight-based antineoplastic drugs between patients enrolled in high-deductible (HD) plans and those not in HD plans (N = 1970). A) No statistically significant difference by enrollment to HD plans was observed in the adjusted mean and median net payment for total and discarded amount of weight-based antineoplastic drugs. B) Mean OOP of total and discarded weight-based antineoplastic drugs was statistically significantly higher for patients enrolled in HD plans. No statistically significant difference in median OOP was found between patients in HD and non-HD plans.